Single treatment with CRISPR gene editing therapy offers hope for hereditary angioedema patients

This post was originally published on News-medical.net

You will shortly be re-directed to the publisher's website

A single treatment with, a CRISPR-Cas9 based gene editing therapy, is enough to replace the daily medication of patients with hereditary angioedema (HAE), a condition characterized by severe, painful and sudden onset of swelling, sometimes resulting in death.